Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU urologists say case is clear for more prostate screening

This article was originally published in Clinica

Executive Summary

Three-quarters of the 346,000 or so new cases of prostate cancer in Europe every year are diagnosed in the early stages of disease, resulting in an 80% survival rate, thanks to screening initiatives. So said the European Association of Urology (EUA) last week, in calls to improve prostate screening (for benign prostatic hyperplasia and cancer) and care for the other leading urological conditions: incontinence and erectile dysfunction.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT042644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel